What if there was an entirely new drug modality to enable the body to produce its own healing proteins in vivo?
We are delivering the next wave of innovation to treat serious illness.
Moderna and AstraZeneca have a strategic option agreement to develop up to forty messenger RNA Therapeutics™ for the treatment of serious cardiometabolic diseases and cancer.
We’ve assembled a team of scientists and drug hunters, executives and visionaries. Our experience is matched only by our passion.
We are enabling an entirely new drug modality across a vast range of diseases—many of which cannot be treated with existing drugs.
watch our video
May 22, 2013
John Reynders will join Moderna in early July as its first Chief Information Officer. | Read more
April 30, 2013
Moderna welcomes Henri A. Termeer, former CEO of Genzyme, to its board of directors. | Read more
March 21, 2013
AstraZeneca and Moderna Therapeutics announce exclusive strategic alliance to develop messenger RNA therapeutics™ in cardiometabolic diseases and cancer. | Read more